IL149420A0 - Heterocyclic substituted pyrazolones - Google Patents
Heterocyclic substituted pyrazolonesInfo
- Publication number
- IL149420A0 IL149420A0 IL14942000A IL14942000A IL149420A0 IL 149420 A0 IL149420 A0 IL 149420A0 IL 14942000 A IL14942000 A IL 14942000A IL 14942000 A IL14942000 A IL 14942000A IL 149420 A0 IL149420 A0 IL 149420A0
- Authority
- IL
- Israel
- Prior art keywords
- heterocyclic substituted
- substituted pyrazolones
- pyrazolones
- heterocyclic
- substituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- AIDS & HIV (AREA)
- Ophthalmology & Optometry (AREA)
- Molecular Biology (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16337799P | 1999-11-04 | 1999-11-04 | |
US09/702,191 US6455525B1 (en) | 1999-11-04 | 2000-10-31 | Heterocyclic substituted pyrazolones |
PCT/US2000/030226 WO2001032653A1 (en) | 1999-11-04 | 2000-11-01 | Heterocyclic substituted pyrazolones |
Publications (1)
Publication Number | Publication Date |
---|---|
IL149420A0 true IL149420A0 (en) | 2002-11-10 |
Family
ID=26859595
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL14942000A IL149420A0 (en) | 1999-11-04 | 2000-11-01 | Heterocyclic substituted pyrazolones |
Country Status (21)
Country | Link |
---|---|
US (2) | US6455525B1 (zh) |
EP (1) | EP1226141A1 (zh) |
JP (1) | JP2003513091A (zh) |
KR (1) | KR20020063179A (zh) |
CN (1) | CN1387528A (zh) |
AU (1) | AU1581101A (zh) |
BG (1) | BG106771A (zh) |
BR (1) | BR0015568A (zh) |
CA (1) | CA2389807A1 (zh) |
CZ (1) | CZ20021569A3 (zh) |
EA (1) | EA200200530A1 (zh) |
HK (1) | HK1048632A1 (zh) |
HU (1) | HUP0203203A2 (zh) |
IL (1) | IL149420A0 (zh) |
IS (1) | IS6366A (zh) |
MX (1) | MXPA02004415A (zh) |
NO (1) | NO20022095L (zh) |
PL (1) | PL355296A1 (zh) |
SK (1) | SK6172002A3 (zh) |
TR (1) | TR200201225T2 (zh) |
WO (1) | WO2001032653A1 (zh) |
Families Citing this family (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6811992B1 (en) | 1998-05-14 | 2004-11-02 | Ya Fang Liu | Method for identifying MLK inhibitors for the treatment of neurological conditions |
US7060822B1 (en) * | 1999-07-30 | 2006-06-13 | Abbott Gmbh & Co. Kg | 2-pyrazolin-5-ones |
US6455525B1 (en) * | 1999-11-04 | 2002-09-24 | Cephalon, Inc. | Heterocyclic substituted pyrazolones |
EP2335700A1 (en) * | 2001-07-25 | 2011-06-22 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis C virus polymerase inhibitors with a heterobicylic structure |
WO2003011287A1 (en) * | 2001-08-03 | 2003-02-13 | Vertex Pharmaceuticals Incorporated | Pyrazolon derivatives as inhibitors of gsk-3 |
SE0104140D0 (sv) * | 2001-12-07 | 2001-12-07 | Astrazeneca Ab | Novel Compounds |
AU2003235798A1 (en) * | 2002-01-10 | 2003-07-24 | F. Hoffmann-La Roche Ag | Use of a gsk-3beta inhibitor in the manufacture of a medicament for increasing bone formation |
SE0302546D0 (sv) | 2003-09-24 | 2003-09-24 | Astrazeneca Ab | New compounds |
SE0200979D0 (sv) | 2002-03-28 | 2002-03-28 | Astrazeneca Ab | New compounds |
AU2002951247A0 (en) | 2002-09-06 | 2002-09-19 | Alchemia Limited | Compounds that interact with kinases |
JP4530855B2 (ja) * | 2002-10-04 | 2010-08-25 | キッセイ薬品工業株式会社 | ピラゾール誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体 |
US7098231B2 (en) * | 2003-01-22 | 2006-08-29 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
US7223785B2 (en) | 2003-01-22 | 2007-05-29 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
US20040242461A1 (en) * | 2003-04-08 | 2004-12-02 | Schneider Michael D. | Modulators of telomere stability |
US6984652B2 (en) * | 2003-09-05 | 2006-01-10 | Warner-Lambert Company Llc | Gyrase inhibitors |
KR101164258B1 (ko) | 2003-12-23 | 2012-07-11 | 아스텍스 테라퓨틱스 리미티드 | 단백질 키나아제 조절제로서의 피라졸 유도체 |
WO2005069906A2 (en) * | 2004-01-16 | 2005-08-04 | Yale University | Methods and compositions relating to vascular endothelial growth factor and th2 mediated inflammatory diseases |
US7582770B2 (en) * | 2004-02-20 | 2009-09-01 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
US7253168B2 (en) * | 2004-04-07 | 2007-08-07 | Neurogen Corporation | Substituted 1-benzyl-4-substituted piperazine analogues |
US20050239791A1 (en) * | 2004-04-07 | 2005-10-27 | Hutchison Alan J | Substituted 1-heteroaryl-4-substituted piperazine and piperidine analogues |
TW200609219A (en) * | 2004-06-17 | 2006-03-16 | Neurogen Corp | Aryl-substituted piperazine derivatives |
US7550598B2 (en) * | 2004-08-18 | 2009-06-23 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
WO2006034121A1 (en) * | 2004-09-17 | 2006-03-30 | Henry Ford Health System | Methods and compositions for use of angiogenesis inhibitors in the prevention and/or control of epilepsy |
JP2008516973A (ja) | 2004-10-15 | 2008-05-22 | タケダ サン ディエゴ インコーポレイテッド | キナーゼ阻害剤 |
CN101119988B (zh) * | 2005-02-16 | 2013-03-06 | 阿斯利康(瑞典)有限公司 | 化学化合物 |
PL1853588T3 (pl) * | 2005-02-16 | 2008-11-28 | Astrazeneca Ab | Związki chemiczne |
WO2006124874A2 (en) * | 2005-05-12 | 2006-11-23 | Kalypsys, Inc. | Inhibitors of b-raf kinase |
MX2007014328A (es) * | 2005-05-16 | 2008-02-12 | Astrazeneca Ab | Compuestos quimicos. |
EP1905762A1 (en) * | 2005-05-30 | 2008-04-02 | Genecare Research Institute Co., Ltd | Pyrazolone derivative |
EP1900728A1 (en) * | 2005-05-30 | 2008-03-19 | Genecare Research Institute Co., Ltd | Pharmaceutical composition comprising pyrazolone derivative |
JP2008543919A (ja) * | 2005-06-21 | 2008-12-04 | アステックス・セラピューティクス・リミテッド | 医薬化合物 |
US8343953B2 (en) | 2005-06-22 | 2013-01-01 | Astex Therapeutics Limited | Pharmaceutical compounds |
EP1933832A2 (en) | 2005-06-23 | 2008-06-25 | Astex Therapeutics Limited | Pharmaceutical combinations comprising pyrazole derivatives as protein kinase modulators |
US8076365B2 (en) * | 2005-08-12 | 2011-12-13 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
US8119655B2 (en) | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
AU2006307657B2 (en) * | 2005-10-28 | 2010-10-28 | Astrazeneca Ab | 4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer |
WO2007123269A1 (ja) | 2006-04-19 | 2007-11-01 | Astellas Pharma Inc. | アゾールカルボキサミド誘導体 |
US20100120717A1 (en) | 2006-10-09 | 2010-05-13 | Brown Jason W | Kinase inhibitors |
GB0704932D0 (en) | 2007-03-14 | 2007-04-25 | Astex Therapeutics Ltd | Pharmaceutical compounds |
WO2008129255A1 (en) * | 2007-04-18 | 2008-10-30 | Astrazeneca Ab | 5-aminopyrazol-3-yl-3h-imidazo [4,5-b] pyridine derivatives and their use for the treatment of cancer |
ATE521609T1 (de) * | 2007-05-04 | 2011-09-15 | Astrazeneca Ab | Aminothiazolylpyrimidinderivate und ihre verwendung bei der behandlung von krebs |
UA99459C2 (en) * | 2007-05-04 | 2012-08-27 | Астразенека Аб | 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer |
EP2167075A4 (en) * | 2007-06-08 | 2012-07-11 | Univ Massachusetts | MIXED LINEAGE KINASES AND METABOLISM DISORDER |
SI2206707T1 (sl) | 2007-10-24 | 2014-11-28 | Astellas Pharma Inc. | Azolkarboksamidna spojina ali njena sol |
US8168670B2 (en) * | 2007-11-21 | 2012-05-01 | Teikoku Pharma Usa, Inc. | Pyrazolone derivative emulsion formulations |
EP2292089A1 (en) | 2008-01-11 | 2011-03-09 | Astellas Pharma Inc. | Model animal having both pain in testis or testis-related discomfort actions and frequent urination |
US20110092452A1 (en) * | 2008-03-05 | 2011-04-21 | The Regents Of The University Of Michigan | Compositions and methods for diagnosing and treating pancreatic cancer |
US8365773B2 (en) * | 2008-03-14 | 2013-02-05 | Mcp Industries, Inc. | Valve device and testing method |
US20090286832A1 (en) * | 2008-05-15 | 2009-11-19 | Kiichiro Nabeta | Narcotic emulsion formulations for treatment of surgical pain |
JP2011522870A (ja) * | 2008-06-11 | 2011-08-04 | アストラゼネカ アクチボラグ | 癌および骨髄増殖性障害の処置に有用な三環式2,4−ジアミノ−l,3,5−トリアジン誘導体 |
US20100034752A1 (en) * | 2008-08-11 | 2010-02-11 | Toru Hibi | Inhalant formulations comprising a bisphosphonate and a pyrazolone derivative and methods for using the same |
JP2012504157A (ja) * | 2008-09-30 | 2012-02-16 | アストラゼネカ アクチボラグ | 複素環式jakキナーゼ阻害剤 |
CN102159229A (zh) * | 2008-11-20 | 2011-08-17 | 帝国制药美国公司 | 吡唑啉酮衍生物制剂 |
WO2010099139A2 (en) | 2009-02-25 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Combination anti-cancer therapy |
MX2011007885A (es) * | 2009-02-26 | 2011-12-08 | Techno Guard Co Ltd | Formulaciones de emulsion de narcoticos para tratamiento de dolor por cancer. |
US8642834B2 (en) | 2009-02-27 | 2014-02-04 | OSI Pharmaceuticals, LLC | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
WO2010099364A2 (en) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
WO2010099138A2 (en) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
JP2014519813A (ja) | 2011-04-25 | 2014-08-21 | オーエスアイ・ファーマシューティカルズ,エルエルシー | 癌薬剤発見、診断、および治療におけるemt遺伝子シグネチャーの使用 |
EP3750544A3 (en) | 2011-11-30 | 2021-03-24 | Emory University | Jak inhibitors for use in the prevention or treatment of viral infection |
WO2013152252A1 (en) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
WO2014099503A1 (en) | 2012-12-20 | 2014-06-26 | Inception 2, Inc. | Triazolone compounds and uses thereof |
US9862708B2 (en) * | 2014-02-14 | 2018-01-09 | Tempest Therapeutics, Inc. | Pyrazolone compounds and uses thereof |
CN104860932B (zh) * | 2015-05-13 | 2018-01-12 | 安阳师范学院 | 一种吡唑啉酮类化合物及其应用 |
CN107935905B (zh) * | 2017-11-28 | 2021-09-17 | 大理大学 | Indiacens A的合成方法 |
US20230032101A1 (en) * | 2019-10-28 | 2023-02-02 | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Five-membered heterocyclic oxocarboxylic acid compound and medical use thereof |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2224141A2 (en) | 1973-04-05 | 1974-10-31 | Serdex Etudes Rech Diffus Expl | 1,3-diphenyl-4-hydroxymethylene-pyrazolinones - their salts and formyl derivs, with analgesic and antiinflammatory activity |
FR2081595A1 (en) | 1970-03-31 | 1971-12-10 | Serdex | 1,3-diphenyl-2-pyrazolin-5-ones - as analgesic and antiinflammatory agents |
DE2045049A1 (de) | 1970-09-11 | 1972-03-23 | Dr Karl Thomae GmbH, 7950 Biberach | Neue Nitrofurandenvate und Ver fahren zu ihrer Herstellung |
IT1032161B (it) * | 1974-12-09 | 1979-05-30 | Minnesota Mining & Mfg | Coloranti merocianinici quaterna rizzati e loro uso per sensibiliz zare spettralmente emulsioni positive dirette agli alogenuri d argento |
DE3728278A1 (de) | 1986-12-17 | 1988-06-23 | Bayer Ag | Herbizide und fungizide mittel auf basis von substituierten pyrazolin-5-on derivaten |
DE3941240A1 (de) | 1989-12-14 | 1991-06-20 | Bayer Ag | Pyrazolin-5-on-derivate |
RU2142946C1 (ru) * | 1992-12-17 | 1999-12-20 | Пфайзер Инк. | Производные пиразола и фармацевтическая композиция, содержащая их |
US5780437A (en) * | 1995-12-14 | 1998-07-14 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
JPH10151868A (ja) * | 1996-11-21 | 1998-06-09 | Konica Corp | 黒色画像形成用色素混合物及びそれを用いた感熱転写記録材料ならびに感熱転写記録方法 |
US6034099A (en) | 1998-11-24 | 2000-03-07 | Cell Pathways, Inc. | Method for inhibiting neoplastic lesions by administering 4-(arylmethylene)- 2, 3- dihydro-pyrazol-3-ones |
DE19909237A1 (de) | 1999-03-03 | 2000-09-07 | Merck Patent Gmbh | Pyrazol-3-on-derivate |
NZ516850A (en) | 1999-07-30 | 2004-09-24 | Abbott Gmbh & Co | 2-pyrazolin-5-ones |
US6455525B1 (en) * | 1999-11-04 | 2002-09-24 | Cephalon, Inc. | Heterocyclic substituted pyrazolones |
-
2000
- 2000-10-31 US US09/702,191 patent/US6455525B1/en not_active Expired - Lifetime
- 2000-11-01 AU AU15811/01A patent/AU1581101A/en not_active Abandoned
- 2000-11-01 KR KR1020027005807A patent/KR20020063179A/ko not_active Application Discontinuation
- 2000-11-01 JP JP2001534804A patent/JP2003513091A/ja active Pending
- 2000-11-01 MX MXPA02004415A patent/MXPA02004415A/es unknown
- 2000-11-01 TR TR2002/01225T patent/TR200201225T2/xx unknown
- 2000-11-01 BR BR0015568-3A patent/BR0015568A/pt not_active Application Discontinuation
- 2000-11-01 PL PL00355296A patent/PL355296A1/xx unknown
- 2000-11-01 SK SK617-2002A patent/SK6172002A3/sk unknown
- 2000-11-01 EP EP00978338A patent/EP1226141A1/en not_active Withdrawn
- 2000-11-01 CN CN00814898A patent/CN1387528A/zh active Pending
- 2000-11-01 CZ CZ20021569A patent/CZ20021569A3/cs unknown
- 2000-11-01 IL IL14942000A patent/IL149420A0/xx unknown
- 2000-11-01 WO PCT/US2000/030226 patent/WO2001032653A1/en not_active Application Discontinuation
- 2000-11-01 EA EA200200530A patent/EA200200530A1/ru unknown
- 2000-11-01 CA CA002389807A patent/CA2389807A1/en not_active Abandoned
- 2000-11-01 HU HU0203203A patent/HUP0203203A2/hu unknown
-
2002
- 2002-04-29 IS IS6366A patent/IS6366A/is unknown
- 2002-05-02 NO NO20022095A patent/NO20022095L/no not_active Application Discontinuation
- 2002-06-04 BG BG106771A patent/BG106771A/xx unknown
- 2002-08-22 US US10/225,670 patent/US6831075B2/en not_active Expired - Lifetime
-
2003
- 2003-01-27 HK HK03100691.9A patent/HK1048632A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
AU1581101A (en) | 2001-05-14 |
WO2001032653A1 (en) | 2001-05-10 |
HUP0203203A2 (hu) | 2003-02-28 |
SK6172002A3 (en) | 2003-01-09 |
US20030162775A1 (en) | 2003-08-28 |
TR200201225T2 (tr) | 2002-08-21 |
BR0015568A (pt) | 2003-06-10 |
JP2003513091A (ja) | 2003-04-08 |
US6455525B1 (en) | 2002-09-24 |
CN1387528A (zh) | 2002-12-25 |
CZ20021569A3 (cs) | 2003-03-12 |
HK1048632A1 (zh) | 2003-04-11 |
EP1226141A1 (en) | 2002-07-31 |
KR20020063179A (ko) | 2002-08-01 |
EA200200530A1 (ru) | 2002-10-31 |
IS6366A (is) | 2002-04-29 |
CA2389807A1 (en) | 2001-05-10 |
NO20022095L (no) | 2002-06-11 |
US6831075B2 (en) | 2004-12-14 |
BG106771A (en) | 2003-03-31 |
MXPA02004415A (es) | 2004-09-10 |
NO20022095D0 (no) | 2002-05-02 |
PL355296A1 (en) | 2004-04-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL149420A0 (en) | Heterocyclic substituted pyrazolones | |
GB9929973D0 (en) | Heterocyclic compounds | |
IL145836A0 (en) | Substituted azoles | |
GB9800575D0 (en) | Heterocyclic compounds | |
IL153787A0 (en) | Imidazole derivatives | |
IL150059A0 (en) | Novel heterocycles | |
IL148058A0 (en) | Substituted 2-dialkylaminoalkylbiphenyl derivatives | |
PL351527A1 (en) | Substituted benzoylpyrazoles as herbicides | |
IL152979A0 (en) | Heterocyclic compounds | |
MXPA00011504A (es) | Derivados heterociclicos sustituidos. | |
AP2002002413A0 (en) | Heterocyclic compounds inhibiting angiogenesi | |
HK1049999B (zh) | 咪唑類衍生物 | |
IL150010A0 (en) | Heterocyclic derivatives | |
GB9916216D0 (en) | Heterocyclic compounds | |
GB9915510D0 (en) | Heterocyclic compounds | |
GB9916218D0 (en) | Heterocyclic compounds | |
GB9916213D0 (en) | Heterocyclic compounds | |
GB9903337D0 (en) | Heterocyclic derivatives | |
GB9929038D0 (en) | Heterocyclic derivatives | |
GB0009452D0 (en) | PTP1B-Inhibiting heterocyclic derivatives | |
GB0001993D0 (en) | Heterocyclic derivatives | |
GB0001972D0 (en) | Heterocyclic derivatives | |
GB9917858D0 (en) | Pyrazoles | |
GB9914173D0 (en) | New heterocyclic compounds | |
SI1224180T1 (en) | Substituted azoles |